News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|May 9, 2024

Adverse Effects Associated with SBRT in Patients With HCC

Author(s)Rahul Gosain, MD, Rohit Gosain, MD, Nina Sanford, MD

The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.

Episodes in this series

A panel of 5 experts on liver cancer

EP. 1 The Basics of Radiation Oncology

A panel of 5 experts on liver cancer

EP. 2 Overview of Interventional Radiology Treatment Options

A panel of 5 experts on liver cancer

EP. 3 Treating Transplant-Ineligible Patients With HCC and Liver-Confined Disease

A panel of 5 experts on liver cancer

EP. 4 Adverse Effects Associated with SBRT in Patients With HCC

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

BGB-B2033 is under evaluation for patients with hepatocellular carcinoma who progressed on or after systemic therapy in a first-in-human phase 1 trial.

FDA Grants Fast Track Designation to GPC3x4-1BB Bispecific Antibody in HCC

December 18th 2025

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer

November 14th 2025

Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.

Radioembolization Plus Chemotherapy Is Feasible in Liver-Dominant NETs

ByMichael C. Soulen, MD

November 9th 2025

A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.

Outlining a Radioembolization/Chemotherapy Regimen for NET Liver Metastases

ByMichael C. Soulen, MD

November 6th 2025

The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.

Searching for Synergy in Liver-Dominant Neuroendocrine Tumors

ByMichael C. Soulen, MD

November 5th 2025

Trending on CancerNetwork

Spotlighting the Top 10 FDA Oncology Approvals in 2025

A Look Back on the Top 10 Oncology Interviews in 2025

Why is Lymphedema Detected So Late in Breast Cancer?

The Evolution of Distress Screening in Cancer Care

Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer